725 related articles for article (PubMed ID: 34453221)
21. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
23. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
[TBL] [Abstract][Full Text] [Related]
24. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
25. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
26. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
28. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
29. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
33. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
Chen B; Dai H; Yang J; Zhang G; Wen C; Xiang X; Lin R; Huang Y
Curr Cancer Drug Targets; 2023; 23(7):564-571. PubMed ID: 36790005
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Yang H; Yang T; Qiu G; Liu J
J Hepatocell Carcinoma; 2023; 10():1435-1443. PubMed ID: 37691972
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Lenvatinib in Combination With PD-1 Monoclonal Antibody and Interventional Treatment for Intermediate-Stage Hepatocellular Carcinoma: Impact on Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Levels: A Retrospective Study.
Zhu J; Wu Y; Zhang H; Yang J; An Y; Shao S; Xia N
Technol Cancer Res Treat; 2024; 23():15330338241256812. PubMed ID: 38802996
[No Abstract] [Full Text] [Related]
38. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
[TBL] [Abstract][Full Text] [Related]
39. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
40. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
